
Candesartan (CS) shows promise as an anti-inflammatory treatment for gonorrhea by inhibiting the NLRP3 inflammasome, reducing caspase-1 activation, IL-1β secretion, and NLRP3 release in N. gonorrhoeae-infected macrophages. The study reveals that CS suppresses NF-κB activity without affecting mitochondrial damage, oxidative stress, or MAPK pathways. CS-induced autophagy partially contributes to its inflammasome-inhibitory effects, highlighting its potential to combat gonorrhea-induced inflammation and address an unmet therapeutic need.
Like
Save
Share